The Tri-Threes Club held its April monthly meeting on the 17th, inviting Academia Sinica Academician and Vice Chairman of the IBMI, Pan-Chyr Yang, to give a special lecture. He believes that many biotech companies in Taiwan are small and medium-sized enterprises, and benign mergers and acquisitions can achieve rapid growth for these enterprises.
Under the theme of "Opportunities for the Development of Taiwan's Biomedical Industry," Pan-Chyr Yang believes that the development of Taiwan's biomedical industry needs to be viewed from aspects such as talent, regulations, scale, and distribution channels. Most Taiwanese enterprises are small and medium-sized, with many startups having single product lines and lacking a complete product portfolio, making it difficult to compete internationally.
Pan-Chyr Yang pointed out that benign mergers and acquisitions can achieve rapid growth for companies. For example, the biotech leader, Bora Pharmaceuticals, has significantly increased its revenue and profits through continuous mergers and acquisitions, and its market value has multiplied many times since its initial public offering. "Benign mergers and acquisitions are the future trend, which is essential for laying out the industry puzzle."
Regarding talent issues, he stated that Taiwanese companies lack comprehensive strategies for attracting overseas talent and talent investment plans. The Taiwanese education system also struggles to cultivate talent with industry experience and expertise in international trade. The industry also lacks systematic workplace training and educational internship resources.
He further pointed out that according to last year's IMD World Talent Ranking Report, Taiwan ranked 20th, indicating a lag in international talent indicators. Language talent has dropped to 41st place, and due to insufficient language talent, Taiwan cannot argue with others effectively. Although Taiwan has cultivated many engineers and researchers, it lacks macro-CEOs (leaders) who can compete globally.
As for regulations, he believes that Taiwan should avoid having health big data controlled by foreign companies, turning Taiwan into a "colony of AI." The government should moderately loosen regulations and establish global health big data companies that combine public welfare and profitability to create an internationally competitive AI medical information powerhouse.
In terms of distribution channels, as most drug channels are controlled by international pharmaceutical companies and lack international brands and channels, he said that the global medical industry has begun to deploy a comprehensive channel model, making competition more intense. Taiwan should make good use of its southbound policy, integrate industries with medical centers, and expand practical distribution channels.
Resource (Mandarin):
